CCR2 and hepatocellular carcinoma: CCR2 antagonist, 747, was able to block TAM recruitment and enhance the efficiency of sorafenib by modulating the CCL2/CCR2 axis, providing a novel therapeutic approach for HCC (Yao et al., 2017).